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special prerequisites of each country. The IBD Ahead Swiss 
National Steering Committee proposes best-practice recom-
mendations adapted for Switzerland.  Methods: The IBD 
Ahead Steering Committee identified key questions and pro-
vided the Swiss Expert Panel with a structured literature re-
search. The expert panel agreed on a set of statements. Dur-
ing an international expert meeting the consolidated out-
come of the national meetings was merged into final 
statements agreed by the participating International and Na-
tional Steering Committee members – the IBD Ahead ‘Opti-
mized Monitoring’ Consensus.  Results: A systematic assess-
ment of symptoms, endoscopy findings, and laboratory mark-
ers with special emphasis on faecal calprotectin is deemed 
necessary even in symptom-free patients. The choice of rec-
ommended imaging methods is adapted to the specific situ-
ation in Switzerland and highlights the importance of ultraso-
nography and magnetic resonance imaging besides endos-
copy.  Conclusion: The recommendations stress the 
importance of monitoring disease activity on a regular basis 
and by objective parameters, such as faecal calprotectin and 
endoscopy with detailed documentation of findings. Physi-
cians should not rely on symptoms only and adapt the moni-
toring schedule and choice of options to individual situations. 
 © 2014 S. Karger AG, Basel 
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 Abstract 
 Background and Aims: The structured IBD Ahead ‘Optimised 
Monitoring’ programme was designed to obtain the opinion, 
insight and advice of gastroenterologists on optimising the 
monitoring of Crohn’s disease activity in four settings: (1) as-
sessment at diagnosis, (2) monitoring in symptomatic pa-
tients, (3) monitoring in asymptomatic patients, and (4) the 
postoperative follow-up. For each of these settings, four mon-
itoring methods were discussed: (a) symptom assessment, (b) 
endoscopy, (c) laboratory markers, and (d) imaging. Based on 
literature search and expert opinion compiled during an in-
ternational consensus meeting, recommendations were giv-
en to answer the question ‘which diagnostic method, when, 
and how often’. The International IBD Ahead Expert Panel ad-
vised to tailor this guidance to the healthcare system and the 
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 Introduction 
 Crohn’s disease (CD) is a chronic inflammatory dis-
ease of the gastrointestinal tract that may lead to irrevers-
ible bowel damage such as strictures or fistulae. Despite 
absence of clinical symptoms, subclinical inflammation 
often persists and reflects the progression of the disease. 
Disease progression, frequently resulting in structural gut 
wall damage, often requires surgical interventions and is 
frequently associated with some loss of organ function. 
Therefore, a shift of the therapeutic target has been evolv-
ing from symptomatic remission towards mucosal heal-
ing to prevent structural gut wall damage. The absence of 
symptoms and lack of inflammatory markers in associa-
tion with mucosal healing has also been termed as ‘deep 
remission’ which has been suggested as a new treatment 
target  [1, 2] . Along the trajectory towards this target, 
however, a relevant number of questions remain open. As 
mucosal healing cannot be expected to occur in all or the 
vast majority of symptom-free patients, the way of disease 
monitoring depends on the treatment target. Based on 
the new treatment targets and subsequent new monitor-
ing challenges, the IBD Ahead programme 2011 identi-
fied the most relevant unanswered questions relating to 
the monitoring of disease activity and progression in CD 
 [3] .
 By means of a structured consensus-finding process, 
key clinical data and experience were collected to define 
the best practice of monitoring in regard to symptom as-
sessment, biological markers, endoscopy, and imaging. 
These data were consolidated to provide case-based evi-
dence to complement the current ECCO guidelines for 
the management of CD. Following the international con-
sensus, the programme encourages adaptation according 
to the situation in the different countries. For  Switzerland, 
several aspects are specific which are not typical for a 
number of countries involved in the consensus process. 
First, faecal calprotectin is already a well-established 
marker to assess the presence or absence (i.e. mucosal 
healing) of mucosal inflammation, which is readily used 
in Switzerland but, mainly due to logistical or reimburse-
ment reasons, much less so in many other countries. Sec-
ond, magnetic resonance imaging (MRI) is accessible for 
most Swiss patients, whereas in other countries such as 
the United States or United Kingdom, computed tomog-
raphy (CT) is easier accessible than MRI. Furthermore, 
ultrasonography (US), an excellent monitoring tool, is 
performed by gastroenterologists in Switzerland, which is 
not the case in many European countries or in the United 
States.
If applicable, for each item evidence or a recommenda-
tion was sought to answer the questions – Which patient? 
When? How often?
 The literature was reviewed to generate evidence-
based recommendations. These were discussed and as-
sessed at national meetings in the 36 participating coun-
tries. When published evidence was lacking, experts at-
tending the national meetings compiled best-practice 
recommendations.
 At the International IBD Ahead Meeting in September 
2011, in Dusseldorf, the consolidated outcome of the lit-
erature reviews plus national meetings’ outputs were 
merged into final statements which were agreed upon by 
the participating International and National Steering 
Committee members.
 Methods 
 Based on an initial data collection, the International 
Steering Committee Meeting selected important unan-
swered questions and areas of uncertainty in the manage-
ment of CD. The areas of main interest concerning the 
monitoring of CD activity were condensed into a frame-
work ( table 1 ) comprising four  clinical settings , namely 
patients at baseline, symptomatic patients, asymptomatic 
patients, and postoperative patients, and four  monitoring 
methods , symptom assessment, endoscopy, laboratory 
markers, and imaging.
 To ensure tracking disease activity reliably during the 
course of the disease, a thorough assessment with detailed 
documentation at diagnosis is important.
 Assessment at Diagnosis 
 Symptom Assessment 
 Symptom assessment should be used in each patient 
during each consultation. In clinical practice, gastroen-
terologists assess symptoms relying on their global clini-
cal judgement. This simple and readily available method 
seems adequately reproducible. The International Con-
sensus recommends using symptom assessment tools in 
all patients and during each consultation to establish a 
baseline value for future comparison (level D). The 
Crohn’s Disease Activity Index (CDAI)  [4] , the Harvey-
Bradshaw Index (HBI)  [5] , and the Inflammatory Bowel 
Disease Questionnaire (IBDQ)  [6–9] are validated tools 
for evaluating symptoms before patients enter clinical tri-
als (level A). A benefit of using the CDAI or HBI is their 
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usefulness for therapeutic decisions at a later time point. 
They provide semi-objective information facilitating in-
terpretation by colleagues in the same or different institu-
tions. But CDAI and HBI might be too complex to be 
performed in daily practice, and there is little evidence 
from literature that using these scores improves out-
comes.
 Endoscopy 
 Endoscopy should be performed in all patients at base-
line to establish location, extent, and severity of disease 
(level D). Independently of stage, lesions should be mea-
sured and documented carefully. Precise standardized de-
scription of endoscopic lesions including type, location, 
depth, and extent is advocated (level D). This may be 
achieved by endoscopic scoring tools such as the Crohn’s 
Disease Endoscopy Index of Severity (CDEIS) or the Sim-
ple Endoscopic Score for Crohn’s Disease (SES-CD).
 Ileocolonoscopy, with visualisation of the terminal il-
eum and all colonic segments, should be performed (lev-
el A)  [1, 10, 11] ; at least two biopsies of every segment and 
the rectum (in areas that appear both normal and abnor-
mal), should be taken to support diagnosis (level D)  [12] .
 For the detection of upper gastrointestinal involve-
ment, gastroscopy is recommended. Double balloon en-
doscopy or enteroscopy should be performed in suspect-
ed cases of small intestinal involvement (level A)  [13–16] .
 Upper gastrointestinal endoscopy and biopsies are 
useful, particularly in paediatric patients and in adult pa-
tients with upper gastrointestinal symptoms (level D) 
 [17–22] .
 Small-bowel capsule endoscopy (SBCE) or enterosco-
py are recommended to support diagnosis in patients 
with a high clinical suspicion of CD with inconclusive il-
eocolonoscopy, gastroscopy and imaging evaluations 
(level B)  [23–35] . Strictures should be excluded previous-
ly (level B). 
 Laboratory Markers – Faecal Markers 
 Routine laboratory and inflammatory marker assess-
ments as well as faecal calprotectin measurement should 
be conducted in all patients to establish a baseline value 
for future comparison  [36–46] (level D).
 The recommended panel of markers are complete 
blood count, liver profile, albumin, iron studies, renal 
function, vitamin B 12 , folic acid, and vitamin D (level D).
 C-reactive protein (CRP) should be measured to assess 
the initial inflammatory response (level D)  [47–51] ; of 
note, patients with CD may have normal CRP levels de-
spite clinical activity and mucosal inflammation (level A) 
 [52] .
 Faecal calprotectin should be assessed as a marker of 
intestinal inflammation (level B); stool analysis and cul-
ture, and  Clostridium difficile toxin testing is also recom-
mended (level D)  [43, 44, 53] .
 Imaging 
 The international consensus recommends performing 
baseline imaging in all patients to assess the extent and 
severity of small bowel involvement and to rule out com-
plications such as fibrostenosing or penetrating disease 
(level D).
 In a patient with complaints suggestive of IBD, US 
should be the first-choice imaging modality  [54–59] (lev-
el B). For an acutely ill patient who is admitted to the 
emergency unit with suspected CD, abdominal multide-
tector CT (MDCT) scanning is the recommended modal-
ity of choice (level B)  [60–62] .
 To evaluate involvement of the small bowel, magnetic 
resonance enteroclysis or enterography are advised for 
staging (level A)  [63–68] . The same diagnostic accuracy 
is provided by CT. CD patients usually undergo multiple 
abdominal imaging during a lifetime. The burden of ion-
izing radiation using CT scans is significant and should 
be minimized (level A)  [69, 70] . Therefore, in Switzerland 
 Table 1.  International IBD Ahead Meeting: the underlying framework for monitoring recommendations in CD
Symptom 
assessment
Endoscopy Laboratory 
markers
Imaging
Assessment at diagnosis
Monitoring in symptomatic patients
Monitoring in asymptomatic patients
Monitoring in post-operative patients
 For each patient scenario and monitoring method, literature findings and summary statements with evidence levels A–D (Univer-
sity of Oxford (UK) Centre for Evidence-Based Medicine, http://www.cebm.net/index.aspx?o=1025) are provided.
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(and also in other Western European countries, depend-
ing on availability) MRI is preferred over CT scan for the 
initial staging  [71] . In the United States it was estimated 
that up to 0.5–2.0% of cancers could be attributed to the 
radiation of CT scans. The risks in other countries were 
found to be comparable (Germany 1.5%, United  Kingdom 
0.6%)  [72–74] . The exact cancer risk of recurrent low-
dose radiation is difficult to calculate but it is definitely 
real. IBD patients are exposed to a significant level of di-
agnostic ionizing radiation over time. The median radia-
tion exposure in patients with CD was found in a retro-
spective study to accumulate to 26.6 mSv (range 0–279) 
during a period of 9 years  [75] .
 For detection of stenosing small bowel lesions in pa-
tients presenting with symptoms suggestive of stricturing 
CD, MRI is superior to barium studies (level B)  [76] . In 
bowel distension, CT enteroclysis is superior to CT en-
terography (although less tolerated by patients), but diag-
nostic accuracy of both is comparable for the detection of 
stenotic lesions (level B)  [77–80] .
 In cases of incomplete colonoscopy due to an impass-
able colonic stricture, colonic inflammatory lesions of the 
segment not explored by endoscopy can be evaluated by 
CT colonography (level B). MDCT techniques are highly 
accurate for the detection of extraintestinal manifesta-
tions, especially for abscesses and fistulae (level A)  [68, 
81] . MRI is the gold standard to image perianal lesions of 
patients with suspicion of CD (level A)  [82–85] . Anorec-
tal US is helpful to evaluate perianal abscesses (level B). 
Transdermal perineal US might be helpful to evaluate the 
exact anatomy of perianal complications (level C)  [86–
92] . In general, MRI is preferred to a CT scan in order to 
avoid radiation.
 Contrast-enhanced ultrasound (CEUS) and small in-
testine contrast ultrasound (SICUS) play a limited role in 
baseline assessment due to lack of standardisation and 
poor accessibility  [93–96] .
 Monitoring in Symptomatic Patients 
 Routine monitoring of patients through symptom as-
sessment, endoscopic evaluation, laboratory markers and 
imaging is important to ensure adequate response to ther-
apeutic interventions and to optimise therapy (level D).
 Symptom Assessment 
 In each consultation, symptom assessment should be 
performed. Persisting symptoms must be evaluated clini-
cally, and appropriate guidance is desirable.
 In regard to the choice of tools, the same recommen-
dations apply as in baseline assessment. In everyday clin-
ical practice, CDAI or HBI are sometimes used for thera-
peutic decisions in patients under immunosuppressive or 
biologic therapy.
 Recommended re-evaluation intervals to evaluate the 
effect of therapeutic options depend on the chosen modal-
ity. Symptom evaluation is done (i) 2–4 weeks after initiat-
ing corticosteroids, (ii) 3–6 months after initiating immu-
nosuppressive therapy (with earlier evaluation of side ef-
fects), and (iii) 8–12 weeks after initiating biologic therapy.
 Endoscopy 
 In patients with unclear clinical presentation, endos-
copy and especially colonoscopy should be performed if 
the result has an impact on treatment decisions, for in-
stance introducing biological therapy (level D). In this 
case, endoscopic confirmation of disease activity is ap-
propriate unless there is other objective evidence of active 
disease (level D). Before endoscopy, calprotectin may be 
used as a surrogate marker for inflammatory activity (lev-
el B)  [42–44, 97] .
 The frequency of endoscopy is directed by clinical 
symptoms (level D). The type of endoscopic assessment 
should be determined by known sites of involvement and 
clinical presentation (level D). Capsule endoscopy or enter-
oscopy may be considered in patients with negative ileoco-
lonoscopy and imaging evaluations (level D)  [24, 98–101] .
 Laboratory Markers 
 Laboratory investigations should be conducted in all 
symptomatic patients (as well as prior to starting therapy) 
to assess disease activity and exclude intercurrent infec-
tion (level D). Blood markers should be used in clinical 
worsening and in suspicion of disease flare (level B)  [102] .
 CRP is a helpful marker to monitor systemic inflam-
mation in symptomatic patients (level A/Swiss consen-
sus: level B)  [102] . Concomitant complete blood count is 
recommended (level B)  [103] . Faecal calprotectin can be 
used as a surrogate marker for inflammatory activity 
(level A)  [42–44, 97] and to discriminate from function-
al symptoms (level C). Faecal cultures should be taken to 
exclude bacterial infections (level D).  C. difficile infection 
should be ruled out  [104, 105] . Faecal cultures for para-
sites  should be taken three times. Especially in patients 
under immunosuppressive therapy, biopsies should be 
taken to search for cytomegalovirus  [106, 107] .
 The frequency of re-assessments will be determined by 
disease severity, treatment type, and therapeutic response 
(level D).
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 Imaging 
 Small Bowel Symptoms 
 For small bowel symptoms, MRI enterography is the 
preferred mode to assess the extent and severity (level A) 
 [63–68] . MRI can detect disease activity at a stricture and 
differentiate between inflammatory or fibrostenotic stric-
ture, but the diagnostic power to discriminate the two has 
not been adequately evaluated (level B). MRI is also suit-
able for monitoring disease activity and evaluating CD 
preoperatively (level B)  [108–110] . Small bowel US might 
also be useful (level B)  [111] . Due to the radiation risks 
associated with CT enterography and barium techniques 
(level A), their routine use is not recommended (level D) 
 [112–114] .
 Complications 
 CT scans are useful in patients with fulminant symp-
toms to detect bowel obstruction, perforation, or toxic 
colon distension (level B)  [60–62] . Abdominal MDCT is 
the modality of choice for an acutely ill CD patient pre-
senting in the emergency room. The MDCT findings 
correlate well with disease activity (level B)  [60–62] . 
Contrast-enhanced CT of the abdomen/pelvis or US are 
useful in acutely ill patients to rule out complications 
such as intra-abdominal abscesses (level B)  [61, 68, 115, 
116] .
 In suspected acute complications such as strictures, 
perforations, abscesses, and obstructions, plain abdomi-
nal US (level B) and/or CT scans should be used (level D) 
 [57, 117, 118] . MRI is accurate in imaging extraluminal 
alterations, too (level A).
 Pelvic MRI (level A) and/or transperineal (level C) and 
rectal US (level B) should be used to assess perianal dis-
ease and to rule out perianal abscess. Transdermal peri-
anal US might enhance the diagnostic accuracy regarding 
perianal fistulae and abscesses (level C)  [82–92] . Imaging 
should be performed in combination with examination 
under anaesthesia (level D).
 Due to radiation risks associated with CT enterogra-
phy, its use should be limited (level D).
 The frequency of conventional radiology and CT are 
directed by the clinical situation (level D). Acute compli-
cations, like abscesses, ileus, or perforation, should be di-
agnosed immediately (level C).
 CEUS and specific components (Doppler flow and 
bowel wall thickness) of US were observed to be appro-
priate to monitor the efficacy of the therapy; however, 
the frequency of the follow-up is not defined (level D). 
CEUS is not frequently used in clinical practice  [93–
96] .
 Monitoring in Asymptomatic Patients 
 As outlined in the Introduction, there is a discrepancy 
between symptoms and inflammatory disease activity. 
The rising importance of new treatment targets such as 
mucosal healing and deep remission require strategies to 
monitor disease beyond symptoms which may include 
laboratory markers, endoscopy, and imaging (level D).
 Symptom Assessment 
 The CDAI or HBI, as well as the IBDQ have been used 
for verifying remission in CD patients (level A). It is not 
common clinical practice to measure these indices in as-
ymptomatic patients. Evidence exists that there is a con-
tinued impact on quality of life by the disease, even when 
inactive. Therefore, determination of IBDQ in patients 
in remission might be of value (level B)  [6–9] . Symptom 
assessment tools should be used during each consulta-
tion (level D), the frequency of which depends on the 
patient’s treatment regimen, typically every 3–6 months 
(level D).
 In general, physicians should wait 3–6 months before 
judging efficacy of immunosuppressive therapy and 8–12 
weeks before judging biologic efficacy (level D). Side ef-
fects need to be evaluated earlier.
 Endoscopy 
 Ileocolonoscopy is recommended in ileocolonic dis-
ease; in patients with upper gastrointestinal involve-
ment, upper gastrointestinal endoscopy is recommend-
ed (level D). Endoscopy in asymptomatic patients may 
be appropriate when there is concern about disease pro-
gression and when therapeutic modifications are consid-
ered (level D). Endoscopic healing is associated with a 
lower rate of hospitalisation, surgery, steroid- and bio-
logical-free remission (level B)  [119–124] . There is insuf-
ficient evidence to recommend routine endoscopy to as-
sess mucosal healing in all patients, but it is likely to be 
appropriate within 6 months of starting biological ther-
apy (level D) and is best performed before stopping bio-
logical therapy (level C)  [125] . Endoscopies without clin-
ical consequence (‘routine assessments’) should be 
avoided (level D).
 Laboratory Investigations 
 Laboratory investigations should be part of the global 
assessment in an asymptomatic patient (level D) at each 
visit (level D). As a marker of inflammation, CRP and to-
tal blood count can be useful to assess inflammation de-
spite absence of clinical symptoms (level B). Calprotectin 
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can be used as surrogate marker for inflammatory activ-
ity (level A).
 Routine monitoring of inflammatory markers should 
be performed on an individual basis and depending on 
the type of medication (e.g. TNF-α; level C) every 3–12 
months (level D). 
 Vitamin D and B 12 assessments may help to detect dis-
ease complications (level B).
 Imaging 
 Imaging in the asymptomatic patient may be appro-
priate when there is concern about disease progression 
and when therapeutic modifications are considered (level 
D). To assess these patients, MRI (enterography, entero-
clysis) or abdominal US is preferred (level D). In asymp-
tomatic patients, there is no indication to use convention-
al radiology or CT (level D). Some clinicians control their 
symptomless patients with US (level D). US may be help-
ful to detect inflammation before clinical symptoms oc-
cur. The frequency of US examinations should be depen-
dent on the individual risk profile of the patient.
 Monitoring in Postoperative Patients 
 It is acknowledged that disease may recur in the ab-
sence of symptoms, and therefore symptoms alone are 
inadequate when monitoring for postoperative recur-
rence (level A)  [126–128] . A combination of symptom 
assessment plus endoscopic evidence of recurrence is the 
present standard of care for assessing outcomes in post-
operative CD.
 Symptom Assessment 
 Symptoms should be assessed within 3 months after 
surgery (level D), followed by regular visits for instance 
every 3 months in the first year after surgery, then every 
6–12 months depending on the risk (level D) as assessed 
preoperatively.
 Endoscopy 
 Ileocolonoscopy is the gold standard to confirm the 
diagnosis of postoperative recurrence by defining the 
presence and severity of morphologic recurrence (level B) 
and predicting the clinical course (level B)  [126, 129–
133] . The frequency of further endoscopies depends on 
the findings of the first endoscopy after surgery, and on 
the future disease course (level D).
 It is recommended to perform ileocolonoscopy be-
tween 3 and 6 months postoperatively to check for re-
lapses after surgery (level D)  [126, 132, 133] . There is no 
evidence that performing ileocolonoscopy more than 
once improves outcomes (level B). Capsule endoscopy is 
a potential alternative in selected patients (level D). Rut-
geerts score should be used to assess recurrence in the 
neo-terminal ileum (level D). 
 Laboratory Investigations 
 Routine laboratory investigations should be conduct-
ed (level D), as well as CRP assessments (level C). Calpro-
tectin can indicate disease recurrence after surgery (level 
C)  [134–136] . Determination of vitamin B 12 is manda-
tory after ileocolonic resection (level D) 6 months post-
operatively.
 Postoperative measurement of faecal markers 
6  months after surgery and after first endoscopy is re-
garded as a suitable non-invasive postsurgery monitoring 
tool (level D).
 There is a disconnection between symptoms and en-
doscopic disease activity, therefore routine monitoring of 
inflammatory markers every 3–6 months is recommend-
ed (level D). The need for vitamin B 12 substitution should 
be checked regularly (level D).
 Imaging 
 US plays a role in detecting postoperative recurrence 
in CD. US should be performed 3 months after small 
bowel resection. In patients at high risk of recurrence, 
US can be performed regularly even when the index en-
doscopy 6 months after surgery is normal. SICUS can be 
a choice to follow-up patients with small bowel resec-
tion. 
 Due to the radiation risks associated with CT enterog-
raphy, its routine use is not recommended (level D) 
whereas MRI enterography is a legitimate choice.
 Conclusion 
 Due to good availability of MRI in Switzerland, one of 
the main characteristics of the country-specific recom-
mendations concerns the reduced use of CT to minimize 
the radiation burden during the course of the disease. 
Currently, positron emission tomography does not play 
a role in the diagnostic management of CD in  Switzerland. 
After establishing a baseline status, endoscopy (in as-
ymptomatic patients) should only be performed if the 
results trigger a therapeutic consequence. To assess in-
flammation even in asymptomatic patients, calprotectin 
can be used as a surrogate marker for inflammatory ac-
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tivity in the gastrointestinal tract. Symptom assessment 
and laboratory evaluation on a regular basis, depending 
also on the type of therapy, should ensure that the in-
flammation is continuously inhibited to achieve a sus-
tained remission.
 Follow-up of asymptomatic patients by US is an op-
tion which is available in Switzerland and that should be 
used more frequently. Calprotectin is well accepted in 
Switzerland and should be part of the standard of care in 
CD as outlined in these recommendations.
 In general, Swiss resources for the monitoring of CD 
patients are excellent. An appropriate use will guarantee 
optimal care for our patients and will bring us closer to 
the treatment goal of preventing irreversible bowel wall 
damage. 
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